Roswell Park at ASCO 2026: GLP-1s and Aggressive Breast Cancer, CAR T in Older Adults, AI-Informed Benchmarking - Takeaways - MDSpire

Roswell Park at ASCO 2026: GLP-1s and Aggressive Breast Cancer, CAR T in Older Adults, AI-Informed Benchmarking

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago

  • By

  • May 25, 2026

  • 9 min

Share

  • 1

    Roswell Park will present research at the ASCO annual meeting from May 29 to June 2, showcasing advancements in cancer care.

  • 2

    GLP-1 receptor agonists may reduce the risk of hormone receptor-positive breast cancer and improve survival in non-diabetic, overweight women.

  • 3

    Challenges in geographic access limit patient recruitment for CAR T-cell therapy clinical trials, affecting treatment availability.

  • 4

    AI systems are increasingly used in breast cancer decision-making, but standardized benchmarking for their accuracy remains limited.

  • 5

    Dr. Eunice Wang will discuss FDA-approved drugs for relapsed/refractory AML, focusing on safe dosage and management of adverse events.

Original Source(s)

Roswell Park at ASCO 2026: GLP-1s and Aggressive Breast Cancer, CAR T in Older Adults, AI-Informed Benchmarking

  • by

  • May 25, 2026

Related Content

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Management of toxicities from antibody – drug conjugates in breast cancer